NRX Pharmaceuticals (STU:B1Q) Growth Rank : 0 (As of Jun. 21, 2024)

View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Growth Rank?

NRX Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

NRX Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of NRX Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NRX Pharmaceuticals (STU:B1Q) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

NRXP:USA

Address

1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801

Website

https://nrxpharma.com

NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines